|
Abstract
Objective: This systematic
review and meta-analysis aimed
to evaluate the effect of
Lixisenatide, a short-acting
glucagon-like peptide 1 receptor
agonist, as an add-on therapy
to insulin in patients with
type 2 diabetes (T2DM). The
primary outcome of interest
was the change in HbA1c levels.
Methods:
A comprehensive literature
search was conducted in major
databases for relevant studies
published up to the present.
Seven studies were included
in the quantitative data synthesis.
The characteristics of the
included studies, including
intervention, design, duration,
sample size, demographics,
baseline characteristics,
and outcome measures, were
summarized in a descriptive
manner. A pooled analysis
was performed to assess the
overall effect of Lixisenatide
on HbA1c levels. Heterogeneity
among the studies was evaluated,
and sensitivity analyses were
conducted when necessary.
Results:
The pooled analysis of
the seven included studies
demonstrated a significant
reduction in HbA1c levels
with Lixisenatide as an add-on
therapy to insulin. The mean
difference (MD) was -0.41%
(95% CI: -0.55 to -0.28),
indicating a clinically meaningful
improvement in glycemic control.
Although heterogeneity was
observed among the studies
(I² = 80%, p < 0.0001),
the overall effect estimate
remained consistent.
Conclusion:
Our systematic review and
meta-analysis provide robust
evidence supporting the efficacy
of Lixisenatide as an add-on
therapy to insulin in lowering
HbA1c levels in patients with
T2DM. The significant reduction
in HbA1c levels indicates
mproved long-term glucose
control, which is associated
with reduced risks of diabetes-related
complications. Clinicians
should consider incorporating
Lixisenatide into the treatment
regimen of patients with T2DM
who require additional glycemic
control beyond insulin monotherapy.
Further research is needed
to explore secondary outcomes
and safety profiles associated
with Lixisenatide in this
patient population.
Key
words: lixisenatide ,
add on therapy, insulin ,
glp-1 receptor agonist, Type
2 diabetes
|
